P-0227 - Surgical resection of liver metastases and survival outcomes metastatic colorectal cancer (mCRC)

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Colon Cancer
Rectal Cancer
Surgery and/or Radiotherapy of Cancer
Presenter Adda Bounedjar
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors A. Bounedjar, K. Bendjebbar, E.M. Si Ahmed
  • CHU Blida, Blida/DZ



CRC liver metastases can be resected after downsizing with intensive chemotherapy schedules, with a strong correlation between the response and resection rates. We evaluated the response rate RR and overall survival (OS) in patients who were treated with resectable CRLM.


Patients eligibility criteria included unresectable liver limited metastases from histologically confirmed advanced colorectal cancer, ECOG PS 0-1 and adequate general condition. Patients (pts) received 6 cycles of chemotherapy followed by evaluating the liver resectability.


183 patients with colorectal cancer metastatic enrolled with 96 liver metastatic from January 2010 to September 2013; M/F, 69/27; Median age, 54 years (range 33-74); ECOG PS 0/1/, 64/32/. Colon 59%, rectal 41% with 69% synchronous and 31% metachronous, after treatment 20 patients became eligible for surgery to remove liver metastases, the liver resectability was 20/96 (20.0%); the predicted 3 years overall survival rates was 39%. The number of R0 cases was 35%. The median survival time for patients was 26 months.


Hepatic metastasectomy is the only curative option for patients (pts) with colorectal liver metastases (CRLM) but the optimal sequence of surgery and chemotherapy has not been established.